1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- manufacturers
- XL092
-
- $30.00
-
2026-07-27
- CAS:2367004-54-2
- Purity: 99.51%
- Supply Ability: 10g
|
| | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- Basic information |
| Product Name: | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- | | Synonyms: | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]-;XL-092;JUN04542;Axl,c-Met/HGFR,Vascular endothelial growth factor receptor,p-MET,XL092,TAM Receptor,p-VEGFR2,Mer,ATP,XL 092,VEGFR,Inhibitor,Tyro3,XL-092,orally,inhibit;N-(4-Fluorophenyl)-N-(4-((7-methoxy-6-(methylcarbamoyl)quinolin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide;Zanzalintinib (XL-092);XL092, 10 mM in DMSO;1-N'-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide | | CAS: | 2367004-54-2 | | MF: | C29H25FN4O5 | | MW: | 528.53 | | EINECS: | | | Product Categories: | | | Mol File: | 2367004-54-2.mol | ![1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- Structure](CAS/20210305/GIF/2367004-54-2.gif) |
| | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- Chemical Properties |
| Boiling point | 840.4±65.0 °C(Predicted) | | density | 1.408±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 25 mg/mL (47.30 mM; Need ultrasonic) | | pka | 13.14±0.46(Predicted) | | form | Solid | | color | Off-white to light brown | | InChIKey | JSPCKALGNNVYOO-UHFFFAOYSA-N | | SMILES | C1(C(NC2=CC=C(OC3C4C(N=CC=3)=CC(OC)=C(C(NC)=O)C=4)C=C2)=O)(C(NC2=CC=C(F)C=C2)=O)CC1 |
| | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- Usage And Synthesis |
| Uses | Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research[1][2]. | | in vivo | Zanzalintinib (10 mg/kg/day; oral; for 14 days) causes substantial tumor growth inhibition in xenograft studies. Zanzalintinib shows 82% and 96% inhibition on p-MET and p-VEGFR2, respectively[1].
Zanzalintinib (compound 8; 3 mg/kg; iv) has a T1/2 of 5.4 hours, a CL of 43 mL/hr kg. Zanzalintinib (3 mg/kg; po) has a T1/2 of 7.1 hours and a Cmax of 11.4 μM for rats[2].
| Animal Model: | Rat[1] | | Dosage: | 3 mg/kg (Pharmacokinetic Analysis) | | Administration: | IV | | Result: | Had a T1/2 of 5.4 hours, a CL of 43 mL/hrkg. |
| | IC 50 | Axl; Mer; VEGFR2: 1.6 nM (IC50); AXL: 3.4 nM (IC50); MER: 7.2 nM (IC50) | | References | [1] J. Hsu, et al. XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile. European Journal of Cancer, Volume 138, Supplement 2, October 2020, Page S16.
[2] Lynne Canne Bannen, et al. Compounds for the treatment of kinase-dependent disorders. WO2019148044A1. |
| | 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-[4-[[7-methoxy-6-[(methylamino)carbonyl]-4-quinolinyl]oxy]phenyl]- Preparation Products And Raw materials |
|